Piper Sandler maintains BillionToOne at Overweight, lowers price target to $130 from $140

Piper Sandler kept BillionToOne's rating at Overweight but reduced its price target from $140 to $130, a 7.1% drop. The new target suggests a 13.1% upside from the Nov 9 close of $114.95.

Original reporting
Published Nov 10, 2026, 12:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Piper Sandler maintains BillionToOne at Overweight, lowers price target to $130 from $140 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The downgrade could lead to short-term sell pressure.

02

Market read

A modest analyst target reduction with limited market impact.

03

What to watch

Potential upcoming product launches or contract wins not reflected in the target.

Relevance 4/10Novelty 2/10Timing: today

Background

Piper Sandler's analyst coverage of BillionToOne includes a revised target price.

Market effects

Minimal impact on the broader sector; only reflects analyst view.

None

None

Counterpoint

The price target cut may be overly pessimistic if the company beats expectations.

Key entities

  • BillionToOne

    Micro‑cap firm covered by Piper Sandler.

  • Piper Sandler

    Equity research analyst firm issuing the target change.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.